A Study to Investigate the Preventive Effect of AG-1749 Against the Recurrence of Gastric And Duodenal Ulcers During Long-Term Treatment With Low Dose Aspirin.

Trial Profile

A Study to Investigate the Preventive Effect of AG-1749 Against the Recurrence of Gastric And Duodenal Ulcers During Long-Term Treatment With Low Dose Aspirin.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 May 2016

At a glance

  • Drugs Gefarnate; Lansoprazole
  • Indications NSAID-induced ulcer
  • Focus Therapeutic Use
  • Sponsors Takeda Pharma
  • Most Recent Events

    • 19 Dec 2008 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
    • 19 Dec 2008 Planned number of patients changed from 812 to 461 as reported by ClinicalTrials.gov.
    • 19 Dec 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top